

Continued from previous page

tient compliance. One size doesn't fit all."

At the press briefing, Dr. Nielsen said "this is a dustup about nothing," adding that the specialty societies had been included on the performance measure development from the start. The initial measures won't cover all the specialties, but it was necessary to show Congress that the profession was serious about quality improvement by getting something started quickly, she said.

The AMA has tried to work with the CMS on quality measures for some time now, and it is "very difficult" to get truly significant data and information that really makes a difference, Dr. Thomas Purdon, former president of the American College of Obstetricians and Gynecologists, said in an interview. However, it's unlikely the data will be accurate or have real meaning unless the specialty societies are involved, "either individually or through the Council of Medical Specialty Societies," he said.

It's true that a number of specialty groups don't feel comfortable that they can meet these time lines, Dr. David Nielsen, executive vice president and chief executive officer of the American Academy of Otolaryngology-Head and Neck Surgery, said in an interview.

There's an assumption that the AMA is going to be responsible for doing all of the

specialty measures, Dr. David Nielsen said. "While those concerns are valid, it isn't going to come to that." What these groups need to remember is [that the] AMA's consortium is run by the specialty societies, a process that's consensus based, he said. (The American Academy of Otolaryngology-Head and Neck Surgery is a consortium member.)

"People who are upset about this aren't comparing it to what would happen if the AMA didn't step in; that CMS would step in and do their own measures. I'd be much happier with consortium measures than any other group of measures, because the consortium is in the best position to produce patient-centered measures of medical outcomes that are driven by physicians, and are relevant and validated," he said.

Physician concerns about CMS's initial draft of the physician voluntary reporting program (PVRP) had also been interpreted on Capitol Hill as a sign of opposition to quality reporting, Dr. Maves noted.

From CMS's perspective, there's no reason why the AMA's agreement shouldn't work in tandem with the PVRP, CMS spokesman Peter Ashkenaz said in an interview.

The voluntary reporting program isn't about developing measures, it's about testing systems "on how well we can use the existing claims-based system to capture the data from the measures," he said. ■

## IT Leaders Set Goals for Health Records

Over the next year or so, leaders in the health information technology community will work on ways to make medication history and some general demographic information available to consumers in a portable health record.

Experts at a Webcast meeting of the American Health Information Community agreed that this is the "low-hanging fruit" that could eventually pave the way for widespread access to portable, consumer-controlled personal health records. The American Health Information Community is an advisory committee to the Department of Health and Human Services.

The development of portable electronic demographic information, or registration information, would be a way to do away with the medical clipboard, HHS Secretary Mike Leavitt said.

"The timeliness of access to medical information is critical to patients," said Nancy Davenport-Ennis, CEO of the National Patient Advocate Foundation and a member of the American Health Information Community. Today, most patients feel they own their medical record but when they go to get lab results from their physician, it can often take days or weeks, she said.

But one of the major hurdles in creating secure and portable patient health records is authentications, said Dr. Reed Tuckson of UnitedHealth Group, who presented information to the group.

Other obstacles include the inability to locate patient information across multiple settings, segmentation of the consumer market, privacy concerns, low levels of consumer trust, few electronic health records to connect to, and the lack of an established business model.

But there have been some successes, said David Lansky, Ph.D., of the Markle Foundation, who presented information to the group. For example, the Department of Veterans Affairs set up a patient portal, and the Department of Defense has a similar program. And some health plans offer pre-populated personal health records. "We're not starting with a blank slate," Dr. Lansky said.

Providing medication history electronically to patients is something that could be done quickly, Dr. Lansky said. The Markle Foundation was one of the groups that helped spearhead efforts to do just that with www.katrinahealth.org, which allowed certain physicians to access drug histories for hurricane evacuees.

—Mary Ellen Schneider

In the successful management of atopic dermatitis

## Confidence from the start with Atopiclair™

### CALMS

#### Rapid relief during flares

- Clinically proven to significantly relieve itching, burning, and pain<sup>1,2</sup>
- Contains glycyrrhetic acid—with anti-inflammatory properties<sup>3</sup>

### RESTORES

#### Replaces what's missing

- Restores key skin lipids<sup>2,4</sup> and hydrates with hyaluronic acid


### PROTECTS

#### Long-term skin support

- Supports normal skin-barrier function which helps prevent recurrence<sup>2,4,5</sup>

#### Addresses safety needs

- No restriction on age or duration of use
- May be used with other topical therapies
- Nonsteroidal cream



Penetration of Atopiclair into compromised stratum corneum

START WITH AND STAY WITH ATOPICLAIR



Available in a 100g tube

Rx Only  
**Atopiclair™**  
NONSTEROIDAL CREAM

www.atopiclairUS.com

References: 1. Belloni G, Pinelli S, Veraldi S. A randomised, double-blind, vehicle-controlled study to evaluate the efficacy and safety of MAS063D (Atopiclair), in the treatment of mild to moderate atopic dermatitis. *Eur J Dermatol.* 2005;15:31-36. 2. Data on file. Chester Valley Pharmaceuticals, Inc., Malvern, PA. 3. Saeedi M, Morteza-Semani K, Ghoreishi M-R. The treatment of atopic dermatitis with licorice gel. *J Dermatol Treat.* 2003;14:153-157. 4. Atopiclair™ Nonsteroidal Cream, prescribing information. 5. Zhai H, Villarama CD, Hafeez ZH, Malbach HI. Efficacy of a topical agent, MAS063D (Atopiclair), in the treatment of sodium lauryl sulphate-induced irritant contact dermatitis. *Exog Dermatol.* 2003;2:301-305.